cDNA Fragments As Novel Anti-Cancer Therapeutics And Diagnostics
Background:
The National Cancer Institute's Hatfield Clinical Research Center
is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize cDNA fragments as antiangiogenic and antitumor
therapy.
Technology:
This invention describes small cDNA fragments of the coding region
for wild type filamin A interacting protein 1-like (FILIP1L),
previously known as (DOC1), and variant 2 of FILIP1L genes. These
cDNA fragments encode proteins that result in the inhibition of
cell migration and motility, induce cell apoptosis and inhibit cell
proliferation. These coding sequences have successfully been
delivered to endothelial cells and tumor cells both in vitro and in
vivo, and have demonstrated significant anti-tumor activity.
In addition, the inventors have for the first time expressed the
recombinant protein and developed antibodies to detect the protein
fragments by Western, ELISA and immunohistochemistry. This
invention could provide for a series of new anti-cancer
therapeutics and for diagnostics.
Further R&D Needed:
- Further characterize the mechanisms of action of these
fragments
- Conduct further work to determine the anti-tumor activity
R&D Status: Pre-clinical
development
IP Status:
- U.S. Provisional Application No. 61/005,363 filed 03 Dec
2007
Value Proposition:
- cDNA fragments that are able to induce apoptosis and inhibit
cell proliferation, migration, and motility
- Ability to develop novel cancer diagnostics and therapeutics
with significant anti-tumor activity
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #777
Revised 11/6/2008
This opportunity is also listed under the following categories: